Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Lincoln
With
University of Kent
NHS Lincolnshire West Clinical Commissioning Group
NHS South Lincolnshire Clinical Commissioning Group
Age
65–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Patients aged 65-85 years with a diagnosis of COPD (according to Global Initiative for Chronic Obstructive Lung Disease criteria: post bronchodilator FEV1/FVC ratio \<0.70) and moderate to severe airflow limitation (FEV1 30-80% predicted) who opt to receive the annual influenza vaccine.
We will also include healthy participants aged 65-85 years without symptoms of lung disease who opt to receive the annual influenza vaccine.
You may not be if
Unable/unwilling to provide informed consent
Any history of allergies, suspected hypersensitivity and/or contraindication to vaccines (e.g egg protein allergy)
Participation in another clinical trial (use of investigational product or device)
Not on optimal treatment (COPD patients only)
Current smokers, exhaled CO \>10 parts per million
Clinical instability, defined as experiencing a COPD exacerbation less than 4 weeks prior to baseline visit, as indicated by treatment with systemic glucocorticosteroids and/or antibiotics and/or hospitalization (COPD only)
An upper/lower respiratory tract infection e.g. common cold, sinus symptoms, pneumonia, which has not resolved four weeks prior to baseline visit
Diagnosis of asthma and/or other relevant lung disease (e.g. history of primary or clinically significant bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease \[e.g. fibrosis, silicosis, sarcoidosis\], active tuberculosis)
Known alpha-1-antitrypsin deficiency
Immunological diseases or known infection with Human Immunodeficiency Virus (HIV)
Any diagnosis of a malignant disease (other than basal or squamous cell carcinoma) in the last 5 years
Currently taking immunosuppressive medications
Diagnosis of diabetes mellitus
Severe renal failure (calculated eGFR less than 60 ml/min)
Liver impairment Child-Pugh B/C and/or active viral hepatitis
Severe psychiatric or neurological disorders (Parkinson's disease or motor neurone disease)
Planned donation of human tissue (blood, organs or bone marrow) during the course of the trial
Clareo Health | Influenza Vaccination and COPD Phenotypes
